" Especially Quorthon."
"Tomas "Ace" Börje Forsberg, known by the stage name Quorthon (17 February 1966 – c. 7 June 2004), was a Swedish musician.
Quorthon formed Bathory (named after the infamous Hungarian countess, Elizabeth Báthory) in 1983 when he was 17 years old"
Nothing funny about a 17 yo mind stuck in a 50 year old body having to make ends meet by working in a boiler room.
Pity or contempt but not amusement.
"Lol! Typical! One day IRWD is slightly red and you clap your gums. SGYP on the othe hand can't even sta in the 3.30's lmao!"
You're avoiding answering, we'll assume assume that a company with a lower share price now than it had 5 years ago is what excites you.
"keeps going, nothing stops the energizer bunny,"
The Ironwood just coming off of its lowest share price ever and now close to but not quite at the share price it had just prior to Linaclotide approval, that's your version of energizer bunny?
"ENGLEWOOD, Colo., May 3, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today the acceptance of three new publications in peer-reviewed scientific forums that report mechanisms of action (MOA) of Ampion™."
Peer-reviewed scientific forums, not journals, is misrepresentation of the peer reviewed journals standard.
"Peer Review: Publication’s Gold Standard
...Scientific journals catalog the contributions, thoughts, and opinions of researchers, investigators, and experts in the field. Authors consider the reputation and quality of a journal prior to submitting a manuscript for consideration.
...The goal of peer review is to determine if an article should or should not be published and to improve the article before publication (Neale & Bowman, 2006). It is a process that entails filtering out manuscripts that are misleading, irrelevant, inaccurate, or that contain potentially harmful content (Kumar, 2009)."
Two posters in the halls at a convention for a couple of days is playing with the term "publication".
AAST Publishes the Journal of Trauma and Acute Care Surgery. AMPE's efforts were either not submitted or were rejected for publication is the Journal. See instructions for Abstract submission at the conventions website.
You gotta wonder what's in it for a couple of slick willies trying to slip some bait and switch past their investors.
"could very well be they purchased the shares from the company rather than open market. we can't really know"
Except for the part where she said,
" As a long-term shareholder in the Company, I have believed in NeuVax for over seven years and have closely monitored its development from an early stage asset to its now significantly expanded portfolio of clinical trials."
As a long term share holder over 7 years before her directorship with the company that averages out to open market purchases ~ 5700/year.
"The IDMC is responsible for compiling this data. Gale will only see recurrence data if IDMC/FDA determine the data is compelling enough to warrant an efficacy halt or a conditional approval with trail continuing and all patients getting NeuVax"
" Gale will not compile data on recurrence rates within the both groups."
If there's no data regarding the number of patients with Disease recurrences in each arm how will the IDMC determine whether the experimental substance is or is not increasing harm to the test patients?
Causing more recurrences than expected would be a safety issue. right?
I believe Neuvax is an effective adjuvant to reduce recurrences in those patients who do not respond to Herceptin. Without knowing the number of recurrences in each arm how can IDMC come to decision on halting or completing the trial?
"Obvious and despicable."
Drek Team and/or Li Dingos are probably here working to keep the share price down.
Obvious yes, despicable maybe.
Every body, even lazy slugs, needs to make a living, right?
Who signs your paycheck?
"shares are on sale"
For all of the yada blah yada blah posts the best the ghosties could do today so far was shake loose half a mil shares even trading among themselves.
Who ever is paying them sure ain't gettin their money's worth..
"The Court has entered an order dismissing with prejudice the litigation against Actavis. Details of the settlement are confidential, and the parties have submitted the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law. The expiration date for the latest expiring Abstral patent listed in the FDA’s Orange Book is September 2019."
"But i still think 57% efficacy, or better will do it "
P value of 0.0001 at interim would be over kill. P = 0.001 is very conservative.
38% efficacy with a probability of being 98.53% true would at least generate discussion.
The O’Brien-Fleming Approach
758 with 656 analyzed randomized 1:1.
"For example, in a clinical trial with a target sample size, N (379), in which treatment group means will be compared, the information fraction at an interim analysis is τ = n/N, where n(328) is the sample size at the time of the interim analysis. If your target sample size is 500 and you have taken measurements on 400 patients then τ = .8"
n/N = 328/379 = τ =.865
"If the clinical trial involves a time-to-event endpoint, then the information fraction is τ = d/D, where D(140) is the target number of events for the entire trial and d(70) is the events that have occurred at the time of the interim analysis."
d/D= 70/140 = τ = 0.5
"The alpha spending function, α(τ), is an increasing function with α(0) = 0 and α(1) = α, the desired overall significance level. In other words, every time you are doing analysis you are in a sense "spending part of your alpha." For the rth interim analysis, where the information fraction is τr, 0 ≤ τr ≤ 1, α(τr) determines the probability of any of the first r analyses leading to rejection of the null hypothesis when the null hypothesis is true."
For N- α(τr) = α(τ1) = .05(.865) = 0.0433
For D- α(τr) = α(τ1) = .05(0.5) = 0.025
"A simple spending function that is a compromise between the Pocock and O'Brien-Fleming functions, is α(τ) = τα, 0 ≤ τ ≤ 1. This leads to a significance level of 0.012 at the interim analysis and a significance level of 0.04 at the final analysis (calculations not shown). There are all types of variations that statisticians have devised."
Do we know which formula the SPA uses to determine halt for efficacy?
"Here you have it ."
It's like this:
If 41 events occurred in the Control arm when they were expected then 29 events occurred in the Experiment arm, to equal 70.events. Had there been no efficacy in the E arm 41 events would have been expected at the same time..
Using Chi squared method-
Recurrences of disease in E arm is
29 p = 0.0609
28 p = 0.0308
27 p = 0.0147
26 p= 0.0067
25 p = 0.0029
If the numbers are 43C 27E there will be discussion re. halting for efficacy.
Dr. Ron DePinho president, University of Texas MD Anderson Cancer Center
"In addition, we have also for diseases that have been treated like HER2 breast cancer, a certain form of breast cancer, Elizabeth Mittendorf here, at MD Anderson, developed a HER2 vaccine. About a quarter of patients will recur with the disease and ultimately succumb to the disease after standard treatment with Herceptin. This safe and effective vaccine, HER2 vaccine, appears to eliminate the recurrence of the disease in the vast majority of those patients that would otherwise recur. So those are some examples, other than a treatment of advanced disease, how we can harness the power of the immune system, both at the front end and at the back end of treatment."
Thursday, Apr 21 2016
On the Dianerehm Show
Is it just me or has the starch gone out of the ghost brigade?
Buck up, youse skunky bestids, it will get worse.
"Short interest way up by 1.8m shares on 4/15/2016"
Ouch. It'll be like passing a prickly pear for the new positions. Especially for those who also got burnt by CPXX.
" it is paid to lie by desperate short hedgies begging us to sell our shares --- all the desperate begging..."
and not doing a good job at all.
When the hired boiler room can't move the needle on share price or volume it's close to firing time.
"they'd have gotten someone from outside if things werent copacetic"
SVP is stop gap until they find somebody from the outside
"Is it just me or that May 10 seems a bit early,"
It's just you.
SEC..................Revised Deadlines For Filing Periodic Reports
($75MM or more and less than $700MM) 75 days 40 days
April 1 to May 10 = 40 days
like within the next 9 trading days?
"Mr Market Always Knows"
Just like he knew about CPXX?
or any number of sudden buyouts
or any number of breaking news events.
Mr Market does OK on with already established companies in the day to day not so much with the binary ground breakers.
" If GALE Shares are so Hot, why does share Price Keep Falling?"
Serious question, you don't have a clue how short hedgies treat mini cap biopharms do you?